Neurocrine Biosciences
NBIX · Nasdaq · United States
Share price · NBIX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when NBIX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 3 Nov 2026+13.4%
- 12 Aug 2026-3.4%
Nothing announced by NBIX that day or the session before.
- 31 Jul 2026-10.1%
- 28 Jul 2026+3.6%
Nothing announced by NBIX that day or the session before.
- 3 Jun 2026+6.6%
- 6 May 2026+8.9%
- 12 Feb 2026-10.4%
- 26 Nov 2025+5.6%
Nothing announced by NBIX that day or the session before.
Share of unusual movement by asset
For each asset, the share of NBIX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(6 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | CRF type 1 receptorSmall molecule | Congenital Adrenal Hyperplasia | |
diazoxide choline(Vykat XR) | Approved | KATP channelSmall molecule | Prader-Willi Syndrome |
Valbenazine(Ingrezza) | Approved | vesicular monoamine transporter 2 (VMAT2)Small molecule | Tardive DyskinesiaHuntington's Disease Huntington's Disease Chorea |
| Phase 3 | Muscarinic M4 receptorSmall molecule | Schizophrenia | |
| Phase 3 | AMPA receptor (positive allosteric modulator)Small molecule | Major Depressive Disorder | |
| Phase 2 | Muscarinic M1 and M4 receptors (agonist)Small molecule | Schizophrenia |
Upcoming events
(13 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (6)
July 2027 (3)
August 2027 (1)
What to watch
October 2027 (1)
What to watch
November 2027 (1)
What to watch
2028 (4)
January 2028 (1)
What to watch
February 2028 (1)
What to watch
April 2028 (1)
What to watch
July 2028 (1)
What to watch
2029 (2)
2031 (1)
December 2031 (1)
What to watch
Regulatory and conference events
(8)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $1.1B | $352M | $648M+ $96M short-term inv. | —$395M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $959M | $327M | $339M+ $57M short-term inv. | —$136M operating cash flow | report ↗ |
| 2026-Q1 | $815M | $296M | $275M+ $1.0B short-term inv. | —$146M operating cash flow | report ↗ |
| 2025-Q3 | $795M | $250M | $348M+ $775M short-term inv. | —$228M operating cash flow | report ↗ |
| 2025-Q2 | $688M | $244M | $272M+ $712M short-term inv. | —$102M operating cash flow | report ↗ |
| 2025-Q1 | $573M | $263M | $202M+ $749M short-term inv. | —$65M operating cash flow | report ↗ |
| 2024-Q3 | $622M | $195M | $357M+ $879M short-term inv. | —$158M operating cash flow | report ↗ |
| 2024-Q2 | $590M | $191M | $148M+ $899M short-term inv. | —$65M operating cash flow | report ↗ |
| 2024-Q1 | $515M | $159M | $404M+ $814M short-term inv. | —$130M operating cash flow | report ↗ |
| 2023-Q3 | $499M | $142M | $302M+ $801M short-term inv. | —$212M operating cash flow | report ↗ |
| 2023-Q2 | $453M | $146M | $168M+ $817M short-term inv. | —$180M operating cash flow | report ↗ |
| 2023-Q1 | $420M | $140M | $112M+ $791M short-term inv. | $77M-$125M operating cash flow | report ↗ |
| 2022-Q3 | $388M | $108M | $220M+ $587M short-term inv. | —$99M operating cash flow | report ↗ |
| 2022-Q2 | $378M | $136M | $171M+ $485M short-term inv. | $17M$138M operating cash flow | report ↗ |
| 2022-Q1 | $311M | $102M | $278M+ $395M short-term inv. | —-$41M operating cash flow | report ↗ |
| 2021-Q3 | $296M | $93M | $314M+ $455M short-term inv. | —$62M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $2.9B | $1.0B | $721M+ $767M short-term inv. | —$783M operating cash flow | report ↗ |
Neurocrine reported full-year 2025 total revenues of $2,860.5M, up 21.4% YoY. GAAP R&D expense was $1,015.7M, up 38.9% YoY, and the company ended the period with $721M in cash and equivalents and GAAP net income of $478.6M.
For 2026, Neurocrine guided INGREZZA net product sales to $2.7–$2.8B, GAAP R&D to $1,200–$1,250M, GAAP SG&A to $1,375–$1,400M, and GAAP and non-GAAP IPR&D to $20M. Pipeline developments include Phase 3 programs for osavampator in major depressive disorder and direclidine in schizophrenia, initiation of a Phase 2 study of NBI-1065890 in tardive dyskinesia, and expansion of the CRF platform into metabolic diseases including obesity.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $2.4B | $731M | $241M+ $843M short-term inv. | —$595M operating cash flow | report ↗ |
| 2023-FY | $1.9B | $565M | $259M+ $781M short-term inv. | —$390M operating cash flow | report ↗ |
| 2022-FY | $1.5B | $464M | $271M+ $726M short-term inv. | —$339M operating cash flow | report ↗ |
| 2021-FY | $1.1B | $328M | $344M+ $371M short-term inv. | —$257M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 54 sales ($79.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-17 | LYONS GARY A · director | Option exercise | 15,000 | $53.64 | $805K | Form 4 |
| 2026-11-17 | LYONS GARY A · director | Open-market sale | 1,200 | $163.11 | $196K | Form 4 |
| 2026-11-17 | LYONS GARY A · director | Open-market sale | 4,011 | $163.94 | $658K | Form 4 |
| 2026-11-17 | LYONS GARY A · director | Open-market sale | 5,689 | $165.15 | $940K | Form 4 |
| 2026-11-17 | LYONS GARY A · director | Open-market sale | 4,100 | $165.90 | $680K | Form 4 |
| 2026-11-17 | LYONS GARY A · director | Option exercise (derivative) | 15,000 | — | — | Form 4 |
| 2026-11-04 | ROBERTS EIRY · Chief Medical Officer | Award / grant (derivative) | 8,314 | — | — | Form 4 |
| 2026-11-04 | ROBERTS EIRY · Chief Medical Officer | Award / grant (derivative) | 1,506 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 687 reporting institutions held 99.4M shares ($12.8B, 98.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 13,385,607 | $1.8B |
| 2 | Dodge & Cox | 5,461,037 | $719.4M |
| 3 | JPMORGAN CHASE & CO | 5,442,067 | $700.5M |
| 4 | AQR CAPITAL MANAGEMENT LLC | 4,938,967 | $650.7M |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4,726,344 | $622.6M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 4,511,904 | $594.4M |
| 7 | STATE STREET CORP | 4,354,526 | $573.7M |
| 8 | TWO SIGMA INVESTMENTS, LP | 3,060,570 | $403.2M |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 2,418,897 | $318.7M |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 2,136,672 | $280.8M |
| 11 | BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,493,813 | $196.8M |
| 12 | WELLINGTON MANAGEMENT GROUP LLP | 1,389,539 | $183.1M |
| 13 | Vestal Point Capital, LP | 1,250,000 | $164.7M |
| 14 | MILLENNIUM MANAGEMENT LLC | 1,247,447 | $164.3M |
| 15 | NORTHERN TRUST CORP | 1,242,830 | $163.7M |